Outcomes Group Number of events Total person-years aIRR (95%CI)

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

Clinical Outcomes with Newer Antihyperglycemic Agents

Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.

1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

The SPRINT Research Group

Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.

LEADER trial: Primary Outcome

HOPE: Heart Outcomes Prevention Evaluation study

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

Corticosteroids in the Management of Hyponatremia, Hypovolemia, and Vasospasm in Subarachnoid Hemorrhage: A Meta-Analysis Cerebrovasc Dis 2016;42:

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

TNT: Baseline and final LDL cholesterol levels

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Updates on CVOT Data and Clinical Comparisons That Matter

on behalf of the LEADER Trial Steering Committee and Investigators

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis S Hajibandeh, S Hajibandeh,

TNT Study: Baseline Characteristics of the Patients

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Rounded incidence values (%) of renal and nonrenal events

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Diabetes Journal Club March 17, 2011

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

Aspirin and Cardioprevention in 2018

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study Vasilios Papademetriou, MD, DSc, Eric.

Predictors of contemporary coronary artery bypass grafting outcomes

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Cystatin C levels and risk of death from all causes

Svend A. Mortensen et al. JCHF 2014;2:

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House

2015 EASD In Review: CV Risk management in t2dm

Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney.

Role of Niacin in Current Clinical Practice: A Systematic Review

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Zachary L. Steinberg et al. JACC 2017;69:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

End Points: ONTARGET vs. HOPE *

FIELD: Primary outcome

Pamela E. Scott et al. JACC 2018;71:

Increase of physical activity over time associated with lower HF risk

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Forest plot of adjusted incidence rate ratio for the primary outcome of rt-PA use for catheter malfunction, and secondary outcomes of bacteremia and catheter.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Outcomes Group Number of events Total person-years aIRR (95%CI) Forest plot DPP-4Is vs BGs Primary Outcomes MI BGs 609.0 909,479.0 1 [Reference] DPP-4Is 1,046.0 1,070,551.6 1.46[1.32-1.61] HF 3,260.5 957,259.3 5,499 1,127,507.4 1.43(1.37-1.50) Stroke 101.9 958,792.0 116 1,130,832.0 0.96(0.74-1.26) Secondary Outcome Composite CVDs 4,149.4 907,963.0 6,879.0 1,067,098.6 1.41[1.36-1.47] DPP-4Is vs SUs SUs 1,004.1 801,475.1 1,096.0 1,088,170.6 0.80[0.74-0.88] 5,755.0 835,978.0 6,485 1,144,086.5 0.82(0.79-0.85) 123.7 838,028.2 129 1,147,890.8 0.76(0.60-0.97) 7,031.6 799,350.8 7,918.0 1,084,259.1 0.83[0.8-0.86] DPP-4Is vs α-GIs α-GIs 842.6 769,739.4 1,108.0 1,101,155.6 0.92[0.84-1.01] 4,412.8 805,723 6,689 1,158,361.5 1.05(1.02-1.10) 108.1 807,552.9 131 1,162,238.5 0.84(0.65-1.09) 5,370.0 767,968.0 8,145.0 1,097,179.4 1.06[1.03-1.1] 0.5 1.0 aIRR 1.5 2.0 Figure S1. Adjusted incidence rate ratio assessing the association between DPP-4Is and cardiovascular risks in each pseudopopulation.